Semaglutide + Pramlintide Combination Effects on Appetite and Eating Habits to Be Investigated in N=40 Obesity Trial

The global epidemic of obesity necessitates effective and individualized treatment strategies. While incretin-based therapies like semaglutide have revolutionized weight management, significant variability in patient response exists. Current standard-of-care often lacks the precision to predict individual treatment success or optimize combination therapies. Understanding the complex interplay between incretin hormones, such as GLP-1 and amylin, and their combined effects on appetite regulation and food preference is crucial for tailoring medical weight loss treatments and improving patient outcomes beyond monotherapy.

This study is designed as a 26-week, double-blind, randomized, placebo-controlled trial aiming to enroll N=40 participants. All participants will initially receive weekly semaglutide injections. After 24 weeks, participants will be randomized to receive either an amylin analog, pramlintide, or placebo as a continuous infusion for an additional two weeks, in addition to their ongoing weekly semaglutide. The primary aims include investigating if pre-treatment physiological tests and questionnaires can predict treatment response, and assessing the effect of the semaglutide-pramlintide combination on various aspects of appetite, food preference, and eating habits.